ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research, and care delivery issues unique to countries and settings with limited health care resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author. Credentialed media can access published articles on the ASCO Publications site using their login information.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing September 25, 2023, 4:00 PM ET:

Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial (Original Report)
Erin F. Gillespie, et al.
Request article

Metastasis-Directed Therapy: A Moving Target Advancing Progress Forward (Editorial)
Matthew Pierre Deek, et al.
Request article

Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks (Original Report)
Melle Sieswerda, et al.
Request article

Publishing September 22, 2023, 4:00 PM ET:

Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma (Original Report)
James J. Driscoll, et al.
Request article

Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting (Original Report)
Surbhi Grover, et al.
Request article

HIV and Early Treatment Outcomes Among Women With Cervical Cancer Treated With Concurrent Chemoradiation in Tanzania (Original Report)
Emmanuel Lugina, et al.
Request article

Sustainable Integration of US Food and Drug Administration–Approved Biosimilars: Pharmacy- Versus Physician-Driven Change (Original Report)
David M. Waterhouse, et al.
Request article

Health Care Contact Days Experienced by Decedents With Advanced GI Cancer (Original Report)
Arjun Gupta, et al.
Request article

Publishing September 21, 2023, 4:00 PM ET:

Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO) (Original Report)
Giulio Francolini, et al.
Request article

Published September 20, 2023, 4:00 PM ET:

Meeting Exercise Recommendations Is Beneficial for Cancer Survivors (Original Report)
Stacey Kenfield, et al.
Request article

Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood Acute Lymphoblastic Leukemia (Editorial) 
Ching-Hon Pui, et al.
Request article 

Real-World Pitfalls of Analyzing Real-World Data: A Cautionary Note and Path Forward (Original Report)
Christin B. DeStefano, et al.
Request article

Published September 19, 2023, 4:00 PM ET:

Which Patients with Rhabdomyosarcoma Do Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96, -2002P studies and SoTiSaR Registry (Original Report)
Ewa Koscielniak, et al.
Request article 

Feasibility and Clinical Acceptability of Automation-Assisted 3D Conformal Radiotherapy Planning for Patients With Cervical Cancer in a Resource-Constrained Setting (Original Report)
Sikudhani Muya, et al.
Request article 

Published September 16, 2023, 4:00 PM ET:

Maximizing Extent of Resection For Non-Eloquent GBM: Fluorescent Dye or Intraoperative MRI? (Editorial)
Guy M. McKhann, et al.
Request article 

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization (Original Report)
Patrick Y. Wen, et al.
Request article 

Published September 15, 2023, 4:00 PM ET:

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649 (Original Report)
Hong Xiao, et al.
Request article 

Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer (Original Report)
Chaya S. Moskowitz, et al.
Request article 

Recently published Journal articles are featured on the homepage of each ASCO Journal website. Credentialed media can directly access these articles using their Media HQ login information on the Journal website. You will only need to log in once to access content for all ASCO Journals:

To apply for ASCO media credentials or renew your credentials, visit ASCO’s Media Headquarters and click “Create Account” or log in with your existing account information. To request your username or reset your password, click “Need Help. After submitting the required documentation, you will receive an email notification once your media credentials are approved. Your access to Journal articles will be activated within one week of approval. As you await access, once you have received notification of approved media credentials, submit your requested articles to Journal Request to receive them by email. 

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.